Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Strand

Showing results (121-130 of 150) with videos related to

Pageof 15
Sort By:
The Journal of Rheumatology|June 1, 1995
Health status instruments / utilitiesN Bellamy, M Boers, D Felson, et al.
Clinical Rheumatology|February 6, 2019
Unmet needs in psoriatic arthritis patients receiving immunomodulatory therapy: results from a large multinational real-world studyRieke Alten, P G Conaghan, V Strand, et al.
The European Respiratory Journal|December 5, 1997
Effect of 1 year daily treatment with 400 microg budesonide (Pulmicort Turbuhaler) in newly diagnosed asthmaticsK Osterman, M Carlholm, J Ekelund, et al.
Lupus|September 30, 2003
Improvement in health-related quality of life in systemic lupus erythematosus patients enrolled in a randomized clinical trial comparing LJP 394 treatment with placeboV Strand, C Aranow, M H Cardiel, et al.
The Journal of Rheumatology|November 1, 1994
A pilot study of anti-CD5 ricin A chain immunoconjugate in systemic lupus erythematosusF J Stafford, T A Fleisher, G Lee, et al.
Annals of the Rheumatic Diseases|January 17, 2009
Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomideJ R Curtis, T Beukelman, A Onofrei, et al.
Arthritis and Rheumatism|June 1, 1995
American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritisD T Felson, J J Anderson, M Boers, et al.
Annals of the Rheumatic Diseases|November 19, 2008
Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD studyR Fleischmann, J Vencovsky, R F van Vollenhoven, et al.
The Journal of Rheumatology|May 22, 2001
Standardizing assessment of adverse effects in rheumatology clinical trials. Status of OMERACT Toxicity Working Group March 2000: towards a common understanding of comparative toxicity/safety profiles for antirheumatic therapiesT G Woodworth, D E Furst, V Strand, et al.
Allergy|April 28, 2009
The size of the disease relevant IgE antibody fraction in relation to 'total-IgE' predicts the efficacy of anti-IgE (Xolair) treatmentS G O Johansson, A Nopp, H Öman, et al.
Pageof 15

Showing results (121-130 of 150) with videos related to

Sort By:
Pageof 15
The Journal of Rheumatology|June 1, 1995
Health status instruments / utilitiesN Bellamy, M Boers, D Felson, et al.
Clinical Rheumatology|February 6, 2019
Unmet needs in psoriatic arthritis patients receiving immunomodulatory therapy: results from a large multinational real-world studyRieke Alten, P G Conaghan, V Strand, et al.
The European Respiratory Journal|December 5, 1997
Effect of 1 year daily treatment with 400 microg budesonide (Pulmicort Turbuhaler) in newly diagnosed asthmaticsK Osterman, M Carlholm, J Ekelund, et al.
Lupus|September 30, 2003
Improvement in health-related quality of life in systemic lupus erythematosus patients enrolled in a randomized clinical trial comparing LJP 394 treatment with placeboV Strand, C Aranow, M H Cardiel, et al.
The Journal of Rheumatology|November 1, 1994
A pilot study of anti-CD5 ricin A chain immunoconjugate in systemic lupus erythematosusF J Stafford, T A Fleisher, G Lee, et al.
Annals of the Rheumatic Diseases|January 17, 2009
Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomideJ R Curtis, T Beukelman, A Onofrei, et al.
Arthritis and Rheumatism|June 1, 1995
American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritisD T Felson, J J Anderson, M Boers, et al.
Annals of the Rheumatic Diseases|November 19, 2008
Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD studyR Fleischmann, J Vencovsky, R F van Vollenhoven, et al.
The Journal of Rheumatology|May 22, 2001
Standardizing assessment of adverse effects in rheumatology clinical trials. Status of OMERACT Toxicity Working Group March 2000: towards a common understanding of comparative toxicity/safety profiles for antirheumatic therapiesT G Woodworth, D E Furst, V Strand, et al.
Allergy|April 28, 2009
The size of the disease relevant IgE antibody fraction in relation to 'total-IgE' predicts the efficacy of anti-IgE (Xolair) treatmentS G O Johansson, A Nopp, H Öman, et al.
Pageof 15